CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC). Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals.
The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4.
The abstract for the RELEVANCE/LY.16 study was presented at ASCO on June 3rd, 2018. This study compared the effects of lenalidomide plus rituximab (R2) to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma.
The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.
The PRODIGE 24/CCTG PA.6 trial results suggest that this pancreatic cancer treatment regimen should become standard practice world-wide. Patients who receive this treatment after surgery are almost twice as likely to survive.
New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (CCTG MAC.12 in Canada), show no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone.
The Canadian Cancer Trials Group's (CCTG) Supportive Care (former Symptom Control) Committee (SCC) is currently seeking individuals with interest and experience in supportive care trials to join the SCC Executive. In broad terms (adapted from the CCTG's Terms of Reference) the roles of the Disease Site Committee (DSC) Executive members are to:
